Company Description
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C.
Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.
Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008.
The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jun 26, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 294 |
| CEO | Sheldon Koenig |
Contact Details
Address: 3891 Ranchero Drive, Suite 150 Ann Arbor, Michigan 48108 United States | |
| Phone | 734 887 3903 |
| Website | esperion.com |
Stock Details
| Ticker Symbol | ESPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434868 |
| CUSIP Number | 29664W105 |
| ISIN Number | US29664W1053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sheldon L. Koenig M.B.A. | President, Chief Executive Officer and Director |
| Benjamin Halladay M.B.A. | Chief Financial Officer |
| Glenn P. Brame | Chief Technical Operations Officer |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications |
| Betty Jean Swartz | Chief Business Officer |
| LeAnne Bloedon M.S. | Vice President and Head of Development |
| John B. Harlow Jr. | Chief Commercial Officer |
| Dr. Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 17, 2026 | 144 | Filing |
| Mar 17, 2026 | 144 | Filing |
| Mar 17, 2026 | 144 | Filing |
| Mar 10, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 8-K | Current Report |
| Jan 20, 2026 | 144 | Filing |
| Jan 12, 2026 | 8-K | Current Report |